Alembic Pharmaceuticals shares in focus on Monday as company acquires 45% stake in Canadian pharma venture

Alembic Pharmaceuticals shares are likely to remain in focus on Monday after the company announced a strategic investment in a newly incorporated Canadian corporation to strengthen its presence in the North American pharmaceutical market.

In a regulatory filing, Alembic Pharmaceuticals informed stock exchanges that it has executed a Shareholders' Agreement with Difgen Holdings LLC and Mr. Sukhad Juneja for investing in 17989377 Canada Inc., a newly incorporated Canadian entity.

Alembic to Hold 45% Stake

Under the terms of the agreement, Alembic Pharmaceuticals will hold a 45% equity stake in the Canadian corporation. Difgen Holdings LLC will also own 45%, while the remaining 10% stake will be held by other investors.

The investment is aimed at establishing a platform for the development, commercialization, distribution, and marketing of pharmaceutical products focused on the Canadian market.

Strategic Expansion into Canada

The partnership marks a significant step in Alembic Pharmaceuticals' international growth strategy. Through the Canadian corporation, the company plans to expand its footprint in Canada by leveraging local opportunities in the pharmaceutical sector.

The newly formed venture will focus on bringing pharmaceutical products to market while strengthening distribution and commercialization capabilities in the region.

Governance Structure

According to the agreement, the board of directors of the Canadian corporation will comprise nominee directors appointed by shareholders along with an independent director. The shareholders will also have customary rights related to participation in key business and strategic decisions.

No Related Party Transaction

Alembic Pharmaceuticals clarified that the parties involved in the agreement are not related to the company's promoter, promoter group, or group companies.

The company further stated that the investment does not qualify as a related party transaction. However, following the investment, the Canadian corporation will become an associate company of Alembic Pharmaceuticals.